- Home
- GLO vs FENC Comparison
GLO vs FENC Comparison
Compare GLO & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 230.8M |
| IPO Year | 2006 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GLO | FENC |
|---|---|---|
| Price | $6.01 | $12.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 102.7K | ★ 166.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,206.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.39 | $5.65 |
| 52 Week High | $6.18 | $13.25 |
Technical Indicators
Market Signals| Indicator | GLO | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 61.87 |
| Support Level | $5.77 | $7.40 |
| Resistance Level | $6.08 | N/A |
| Average True Range (ATR) | 0.08 | 0.75 |
| MACD | 0.02 | 0.22 |
| Stochastic Oscillator | 82.17 | 69.64 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.